REG - Kanabo Group PLC - Directorate Change

KanaboAnnouncement

06/01/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250106:nRSF1419Sa&default-theme=true

RNS Number : 1419S  Kanabo Group PLC  06 January 2025

Kanabo Group Plc
("Kanabo" or the "Company")

Board Changes

Kanabo Group plc (LSE: KNB), a health tech company with digital health
services and specialist medicines, announces that Mr David Tsur will be
stepping down from the Board of Directors with effect from 30 January 2025. Mr
Tsur has served as a member of the Board since Admission in early 2021 and
held the position of Chairman for more than 2 years. He has been part of the
Kanabo journey since 2018.

Avihu Tamir, CEO of Kanabo, commented:

"David has personally mentored me since the earliest days of Kanabo and has
been integral to some of our most significant achievements. His wealth of
experience, unwavering support, and commitment to our mission have been
invaluable not only to the Company but also to my own journey. I extend my
gratitude to David for everything he has done for Kanabo, and I wish him the
very best."

Mr Ian Mattioli, Chairman of the Board of Directors, said:

"On behalf of the entire Board, I would like to express our sincere gratitude
to David for his contributions to Kanabo. He has served the Company
professionally and committedly, and we are grateful for his invaluable
insights and guidance. We wish him all the best as he embarks on new
opportunities."

Kanabo further announces its intention to appoint a new UK-based Director to
the Board. A separate announcement will be made in due course.

 

Enquiries:

 

 Kanabo Group plc

 Avihu Tamir, Chief Executive Officer

 Ian Mattioli, Non-Executive Chair of the Board
 Peterhouse Capital Ltd (Financial Adviser)        +44 (0)20 7469 0930

 Guy Miller / Lucy Williams / Charles Goodfellow

 

About Kanabo Group plc

Kanabo Group plc (LSE: KNB) is a digital health company committed to
transforming patient care through its innovative technology platform and
specialised treatment offerings. Since its inception in 2017, Kanabo has been
focused on researching, developing, and commercialising regulated medicinal
cannabis-derived formulations and therapeutic inhalation devices.

Kanabo's NHS-approved online telehealth platform, The GP Service, provides
patients with video consultations, online prescriptions, and primary care
services. Leveraging its telehealth capabilities, in February 2023, Kanabo
launched Treat-It, an online clinic focused on chronic pain management that
provides patients with secondary care. In June 2024, the Treat-It partnership
was expanded to 14 other in-pharmacy locations.

With its two complementary business divisions, Kanabo has established itself
as an end-to-end digital health provider. It offers telehealth consultations,
prescriptions and tailor-made treatments.

The Company's partially owned subsidiary, Kanabo Agritec Ltd, is a cultivation
consultancy supporting cannabis businesses in developing new farms through
infrastructural, research, and product guidance. These farms deliver
high-quality raw materials for Kanabo's formulas and product line.

At Kanabo Group Plc, we are dedicated to providing patients with the highest
quality medical treatments and more accessible healthcare experiences.

Visit www.kanabogroup.com (http://www.kanabogroup.com/) for more information.

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOAFLFIDLAIVIIE